ClinVar Miner

Submissions for variant NM_000492.4(CFTR):c.3209G>A (p.Arg1070Gln)

gnomAD frequency: 0.00006  dbSNP: rs78769542
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 17
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
PharmGKB RCV000660859 SCV000783098 drug response ivacaftor response - Efficacy 2021-03-24 reviewed by expert panel curation PharmGKB Level of Evidence 1A: Level 1A clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation. Annotations of drug labels or clinical guidelines must give prescribing guidance for specific variants (e.g. CYP2C9*3, HLA-B*57:01) or provide mapping from defined allele functions to diplotypes and phenotypes to be used as supporting evidence for a level 1A clinical annotation. Level 1A clinical annotations must also be supported by at least one publication in addition to a clinical guideline or drug label with variant-specific prescribing guidance.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001580449 SCV000052172 uncertain significance not specified 2022-03-10 criteria provided, single submitter clinical testing Variant summary: CFTR c.3209G>A (p.Arg1070Gln) results in a conservative amino acid change located in the ABC transporter type 1, transmembrane domain of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00061 in 251348 control chromosomes in the gnomAD database, including 3 homozygotes. This frequency is not significantly higher than expected for a pathogenic variant in CFTR causing Non-classic Cystic Fibrosis (0.00061 vs 0.013), allowing no conclusion about variant significance. This variant has been reported in several patients with classic CF, non-classic CF, or CBAVD and in several patients it was observed in cis with p.S466X forming a complex allele (example, Krasnov_2008, Mercier_1994, Kanavakis_1005, Savov_1994, Tzetis_2007, Feldmann_2003, Sosnay_2013, Furlan_2016, Lucarelli_2015, Palermo_2016, Behar_2017, Ivanov_2018, Salvatore_2019). The variability in genotyping and non-informative genotypes reported in some of these studies confound the ascertainment of these reports as functional transmissions among genotyped affected individuals. Available patient data suggests that this variant alone is expected to cause mild diseases such as CF/NC and/or CBAVD, while in cis with p.S466X variant, it causes classic CF (Krasnov_2008). Although this variant is able to mature and reach the cell surface and was found to have no significant effect on chloride transport, it was found to cause relatively subtle channel defects with functional consequences of a lower open probability of the channel, lower cyclic AMP-stimulated iodide efflux, and lower bicarbonate transport (Seibert_1996, Krasnov_2008, Sosnay_2013, Choi_2001). In these studies, while maturation assay was performed on HEK-293, MDCK and COS cells, channel function and channel transport assays were performed on HEK293 and CHO cells. In FRT cells, however, chloride transport as well as maturation was found to be significantly reduced for this variant at 20.5% of normal but increased to 32.9% of normal after Ivacaftor treatment (Van Goor_2014). These functional differences might be due to different cell lines being used in different studies and technical backgrounds; however, all these studies are suggestive of a mild functional impairment for the variant in isolation. Multiple clinical laboratories have classified this variant with conflicting assertions ranging from pathogenic (n=6), VUS (n=3) and Benign (n=1), while the CFTR2 database has classified this variant as 'indeterminate' for CF-causation. The variant's presence in cis with a truncating mutation, its association with CF/NC, CBAVD or other CFTR-RDs, and frequency data in South Asian are suggestive of a variable penetrance associated with this variant. A recent publication of policy recommendations towards improvement of the best practice guidelines for preimplantation genetic diagnosis of CF also reports this variant as a 'common variant with varying or indeterminate clinical consequences' (Girardet_2015). Additionally, CFTR2 database includes these statements about the variant: "The drug Ivacaftor (Kalydeco) has been approved in some countries for individuals with this variant. Because of this [clinical] variability, it is very important that CLINICAL CRITERIA ALONE be used to determine whether a person with this variant has CF. Because the clinical manifestations of CF can vary over the course of a person's lifetime, people who have this variant plus a variant that is known to cause CF should have periodic check-ups with their doctor even if they have no clinical signs or symptoms of CF at the present time." Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic.
Counsyl RCV000046825 SCV000220326 likely pathogenic Cystic fibrosis 2014-05-18 criteria provided, single submitter literature only
Eurofins NTD LLC (GA) RCV000724647 SCV000227629 pathogenic not provided 2015-04-28 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV000724647 SCV000885179 pathogenic not provided 2018-04-22 criteria provided, single submitter clinical testing The c.3209G>A; p.Arg1070Gln variant (rs78769542) has been observed in the compound heterozygous state in patients diagnosed with cystic fibrosis with pancreatic insufficiency (see link to CFTR2 database), or mild and atypical CFTR-related disorders, such as chronic pancreatitis and congenital absence of vas deferens (Feldmann 2003, Krasnov 2008), but its effects in the homozygous state are unknown. It is reported as pathogenic or likely pathogenic by several laboratories in Clinvar (Variation ID: 35866) and is observed in the South Asian population at an overall frequency of 0.46% (141/ 30766 alleles, 3 homozygotes) in the Genome Aggregation Database. The arginine at codon 1070 is highly conserved and computational algorithms (PolyPhen-2, SIFT) predict that the variant has an impact on the protein. Functional characterization of the variant protein is inconclusive on the expression level of the mature protein (Cotten 1996, Seibert 1996, Sosnay 2013, Van Goor 2014), but indicates an observable decrease in anion transport activity (Choi 2001, Seibert 1996, Sosnay 2013, Van Goor 2014). Based on available information, the p.Arg1070Gln variant is classified as pathogenic, with a variable presentation of clinical phenotypes. References: Link to CFTR2 database: https://www.cftr2.org/ Choi J et al. Aberrant CFTR-dependent HCO3- transport in mutations associated with cystic fibrosis. Nature. 2001;410(6824):94-7. Cotten J et al. Effect of cystic fibrosis-associated mutations in the fourth intracellular loop of cystic fibrosis transmembrane conductance regulator. J Biol Chem. 1996;271(35):21279-84. Feldmann D et al. CFTR genotypes in patients with normal or borderline sweat chloride levels. Hum Mutat. 2003;22(4):340. Krasnov K et al. Localization studies of rare missense mutations in cystic fibrosis transmembrane conductance regulator (CFTR) facilitate interpretation of genotype-phenotype relationships. Hum Mutat. 2008;29(11):1364-72. Seibert F et al. Disease-associated mutations in the fourth cytoplasmic loop of cystic fibrosis transmembrane conductance regulator compromise biosynthetic processing and chloride channel activity. J Biol Chem. 1996;271(25):15139-45. Sosnay PR et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet. 2013;45(10):1160-7. Van Goor F et al. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros. 2014;13(1):29-36.
Mendelics RCV000046825 SCV000886355 uncertain significance Cystic fibrosis 2018-11-05 criteria provided, single submitter clinical testing
Blueprint Genetics RCV000724647 SCV000927819 uncertain significance not provided 2018-07-24 criteria provided, single submitter clinical testing
Baylor Genetics RCV001004301 SCV001163178 pathogenic Cystic fibrosis; Congenital bilateral aplasia of vas deferens from CFTR mutation criteria provided, single submitter clinical testing
CFTR-France RCV001009383 SCV001169236 pathogenic Cystic fibrosis; CFTR-related disorders 2015-07-03 criteria provided, single submitter curation when the variant is in trans with another CF-causing variation, can either result in CF or in a CFTR-RD
Ambry Genetics RCV001019233 SCV001180564 pathogenic Inborn genetic diseases 2018-03-30 criteria provided, single submitter clinical testing The p.R1070Q pathogenic mutation (also known as c.3209G>A), located in coding exon 20 of the CFTR gene, results from a G to A substitution at nucleotide position 3209. The arginine at codon 1070 is replaced by glutamine, an amino acid with highly similar properties. Functional studies have shown that this mutation does not affect protein processing (Seibert FS et al. J. Biol. Chem., 1996 Jun;271:15139-45; Sosnay PR et al. Nat. Genet., 2013 Oct;45:1160-7), but it was observed to decrease the open probability of the channel (Seibert FS et al. J. Biol. Chem., 1996 Jun;271:15139-45). This mutation has been reported as a variant of varying clinical consequence (VVCC) (Sosnay PR et al. Pediatr. Clin. North Am., 2016 08;63:585-98; The Clinical and Functional TRanslation of CFTR (CFTR2); available at http://cftr2.org. Accessed March 30, 2018); when in trans with a second disease causing mutation it may result in cystic fibrosis, CFTR-related disorders, or no phenotype (Bombieri C et al. Semin Respir Crit Care Med, 2015 Apr;36:180-93; Girardet A et al. Eur. J. Hum. Genet., 2016 Apr;24:469-78). Of note, this mutation has also been observed as part of a complex allele with p.S466* (Krasnov KV et al. Hum. Mutat., 2008 Nov;29:1364-72; Lucarelli M et al. Mol. Med., 2015 Apr;21:257-75). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
Centogene AG - the Rare Disease Company RCV000046825 SCV001424390 pathogenic Cystic fibrosis criteria provided, single submitter clinical testing
Invitae RCV000046825 SCV001718362 benign Cystic fibrosis 2021-12-15 criteria provided, single submitter clinical testing
Genome-Nilou Lab RCV000046825 SCV001810354 likely pathogenic Cystic fibrosis 2021-07-22 criteria provided, single submitter clinical testing
Institute of Reproductive Genetics, University of Münster RCV001642236 SCV001860340 pathogenic Obstructive azoospermia 2022-03-16 criteria provided, single submitter clinical testing
Genome Diagnostics Laboratory, The Hospital for Sick Children RCV000046825 SCV002507377 uncertain significance Cystic fibrosis 2019-08-29 criteria provided, single submitter clinical testing
PerkinElmer Genomics RCV000724647 SCV002019251 pathogenic not provided 2021-04-07 no assertion criteria provided clinical testing
Genome Diagnostics Laboratory, The Hospital for Sick Children RCV002228060 SCV002507463 pathogenic CFTR-related disorders 2019-08-29 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.